Testing pirtobrutinib and rituximab for mantle cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug combination (pirtobrutinib plus rituximab) for people with mantle cell lymphoma who have not yet received any treatment and do not have symptoms. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have mantle cell lymphoma and have never been treated for it (except for a spleen removal for diagnosis).
- You have no symptoms from the lymphoma (like fever, night sweats, or weight loss).
- Your lymphoma is stable and not getting worse for at least 3 months.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- Your blood counts and organ function meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
This trial tests adding the targeted therapy orelabrutinib (a BTK inhibitor) to standard chemotherapy (bendamustine) and immunotherapy (rituximab) for people with high-risk mantle cell lymphoma who have not had treatment before. The goal is to see if the combination works better at controlling the cancer.
This trial tests a combination of two targeted drugs for people with mantle cell lymphoma that has come back or stopped responding after prior treatment with a BTK inhibitor. The goal is to see if this new combination can effectively shrink tumors.
This trial tests a combination of two medications, pirtobrutinib and rituximab, for people newly diagnosed with low- or medium-risk mantle cell lymphoma. It aims to see if this approach is effective and safe without needing chemotherapy.
Hear when a new Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.